Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
UroGen Pharma Ltd.
| Metric | UroGen Pharma Ltd. URGNHealthcare |
|---|---|
| Quality Score | 49 / 100 |
| Revenue (latest) | $110M |
| Net income (latest) | −$153M |
| Operating margin | −113.7% |
| Net margin | −139.8% |
| Return on equity | 145.5% |
| Return on assets | −76.6% |
| Return on capital (ROCE) | −81.1% |
| Debt / equity | — |
| Revenue growth (YoY) | 21.4% |
| Altman Z″ (distress) | -15.59 |
| Accruals / assets | 4.5% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.